|
|
 |
|
 |
|
|
"I would like to really thank you and your team - given the amount of time it took me to simply look at the results you have generated so far makes me realize in small part the gargantuan task that you completed so quickly for us. The availability of these data will be extremely helpful to us with the investors on our board as well as the potential investors with whom we will be meeting."
— CEO,
Small Biotech Company
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
| Fortune Magazine rates inVentiv Health #15 of the Fastest Growing Companies. |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
In order to respond to our clients’ needs for efficient access to concentrated patient populations; iCS has established the inVentiv Clinical Global Alliance network. The purpose of this network is to provide an integrated, responsive global network to offer efficient patient trials beyond the domestic US. Alliance members will have passed quality assessments and will usually provide equity or other provisions in the alliance agreement to assure iCS of a long term, meaningful collaboration.
Taking this integrated alliance approach offers rapid access to these markets and brings immediate credibility and a history of performance. The alternative start-up approach would require excessive time and would require investments that would not be consistent with the competitive value-driven pricing that iCS delivers to the market today.
In the nearer term, we hope to make a similar announcement(s) with respect to Eastern and Western Europe. Longer term, iCS intends to capitalize on our existing presence in India and Taiwan to include a broader Asian capability for clinical trial execution.
|
|
|
|
|
|
|
